Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 6/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31576025 | 0.91 | ESR2 (0.49) | RIPK1HDAC1ESR2NR1H2MAPK1 | |
| SCHEMBL12694450 | 0.89 | HDAC1 (0.48) | RIPK1HDAC1ESR2NR1H2MAPK1 | |
| SCHEMBL15783749 | 0.87 | HDAC1 (0.53) | RIPK1HDAC1ESR2NR1H2MAPK1 | |
| SCHEMBL12694452 | 0.85 | HDAC1 (0.54) | RIPK1HDAC1ESR2NR1H2MAPK1 | |
| SCHEMBL19657617 | 0.84 | RIPK1 (0.64) | RIPK1ESR2NR1H2MAPK1USP2 | |
| SCHEMBL856288 | 0.83 | RIPK1 (0.48) | RIPK1HDAC1ESR2NR1H2MAPK1 | |
| SCHEMBL13765601 | 0.83 | RIPK1 (0.48) | RIPK1ESR2NR1H2MAPK1USP2 | |
| SCHEMBL30405260 | 0.83 | RIPK1 (0.48) | RIPK1HDAC1ESR2NR1H2MAPK1 | |
| SCHEMBL2727759 | 0.82 | RIPK1 (0.47) | RIPK1ESR2NR1H2MAPK1USP2 | |
| SCHEMBL3762084 | 0.82 | RIPK1 (0.47) | RIPK1ESR2NR1H2MAPK1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | RIPK1 1682/4885HDAC1 264/4885ESR2 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.